NTRK1 and neoplasm: In the last two decades, promising preclinical data on the specific molecular mechanisms of NTRK gene fusions resulted in several clinical trials and accelerated the FDA approval of the selective, tumor agnostic NTRK inhibitors larotrectinib and entrectinib (pan-TRK, ROS1, and ALK inhibitor), both of which target a variety of solid tumors in the pediatric and adult populations harboring an NTRK fusion [2, 30–35].